A scientific statement regarding CPET interpretation in patients with congenital HD across their lifespan has been published by the AHA.
Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback